Selection of Cytochrome b Mutants Is Rare among Plasmodium falciparum Patients Failing Treatment with Atovaquone-Proguanil in Cambodia-Reference-Cited by-同舟云学术

Selection of Cytochrome b Mutants Is Rare among Plasmodium falciparum Patients Failing Treatment with Atovaquone-Proguanil in Cambodia

Published:2021-02-17 Issue:3 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lin Jessica T.¹^ORCID,Waltmann Andreea¹,Moser Kara A.¹,Park Zackary¹,Na Yu Bin¹,Aydemir Ozkan²,Brazeau Nicholas F.¹,Gosi Panita³,Marsh Patrick W.²,Muller Meredith S.¹,Spring Michele³^ORCID,Sok Somethy⁴,Bailey Jeffrey A.²,Saunders David L.³⁵,Lon Chanthap⁶,Wojnarski Mariusz³

Affiliation:

1. Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

2. Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA

3. Department of Bacterial and Parasitic Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

4. Department of Health, Ministry of National Defense, Phnom Penh, Cambodia

5. U.S. Army Research Institute of Infectious Diseases, Frederick, Maryland, USA

6. Armed Forces Research Institute of Medical Sciences, Phnom Penh, Cambodia

Abstract

Atovaquone-proguanil remains effective against multidrug-resistant Plasmodium falciparum in Southeast Asia, but resistance is mediated by a single point mutation in cytochrome b ( cytb ) that can arise during treatment. Among 14 atovaquone-proguanil treatment failures in a clinical trial in Cambodia, only one recrudescence harbored the cytb mutation Y268C.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01249-20

Reference18 articles.

1. Atovaquone-Proguanil in Combination With Artesunate to Treat Multidrug-Resistant P. falciparum Malaria in Cambodia: An Open-Label Randomized Trial

2. The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment

3. A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil

4. Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis

5. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-25

2. Amplicon Deep Sequencing Reveals Multiple Genetic Events Lead to Treatment Failure with Atovaquone-Proguanil in Plasmodium falciparum;Antimicrobial Agents and Chemotherapy;2023-06-15

3. Efficacy of three anti-malarial regimens for uncomplicated Plasmodium falciparum malaria in Cambodia, 2009–2011: a randomized controlled trial and brief review;Malaria Journal;2022-09-07